My ePortfolio Register   

AACR 2014 /
Promising advances in the treatment of lung cancer using MK-3475 as an immune checkpoint inhibitor

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1687
Rating:

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Dr Gandhi talks to ecancertv at the AACR conference about her study of MK-3475 which identified a lung cancer patient subset with high levels of PD-L1 which reacted favourably. 

Read the article for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence